- Kiadis Pharma Netherlands BV
- Biofrontera Pharmaceuticals GmbH
- Solvay SA
- Bayer AG
- Unilever PLC
- Oxford BioMedica PLC
- University of Bristol
- Johnson & Johnson
- Janssen Pharmaceutica NV
- Schering AG
- Schwarz Pharma AG
- Johnson Matthey PLC
- Procognia Ltd.
- Sense Proteomic Ltd.
- Celera Corp.
- Deltagen Inc.
- Bristol-Myers Squibb Co.
- Biofrontera and Kiadis agree to merge; withdrawn
- Biofrontera and Kiadis ally on neuropathic pain therapeutics
- ScreenTec gives Bayer access to single-measurement screening
- Kiadis, U. Bristol to discover neuropathic pain therapies
- Biofrontera Pharmaceuticals raises €10.8mm with seed round
- Biofrontera Pharma grosses $11.5mm in private placement
- Screentec raises €6.5mm in first round financing
- Procognia acquires Sense Proteomic
- Celera acquires Axys Pharmaceuticals
- Deltagen buying old CombiChem unit from BMS
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.